SCHEMBL20190992

SCHEMBL20190992

C=CC(=O)Nc1ccc(Nc2ccc(NC(=O)c3cccc(-c4ccn[nH]4)n3)cc2)cc1

nearest known ligand 0.86

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
IRAK1 P51617 8/20 0.86
MAP3K19 Q56UN5 1/20 0.80
IRAK4 Q9NWZ3 2/20 0.56
BCAT2 O15382 1/20 0.43
EGFR P00533 4/20 0.42
SRC P12931 1/20 0.42
ATR Q13535 1/20 0.42
CDK14 O94921 1/20 0.42
CCNY Q8ND76 1/20 0.42
POLB P06746 1/20 0.40
BTK Q06187 1/20 0.39
CNR2 P34972 1/20 0.39
TGM2 P21980 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20190995 0.93 IRAK1 (1.00) IRAK1MAP3K19IRAK4BCAT2EGFR
SCHEMBL20206093 0.89 IRAK1 (1.00) IRAK1MAP3K19IRAK4BCAT2EGFR
SCHEMBL20206218 0.89 IRAK1 (1.00) IRAK1MAP3K19IRAK4BCAT2EGFR
SCHEMBL20206219 0.85 IRAK1 (1.00) IRAK1MAP3K19IRAK4BCAT2EGFR
SCHEMBL20206153 0.83 IRAK1 (0.75) IRAK1MAP3K19IRAK4BCAT2EGFR
SCHEMBL20206143 0.82 IRAK1 (0.68) IRAK1MAP3K19IRAK4BCAT2
SCHEMBL24021462 0.82 IRAK1 (0.68) IRAK1MAP3K19IRAK4BCAT2ATR
SCHEMBL20206262 0.82 IRAK1 (0.68) IRAK1MAP3K19IRAK4BCAT2ATR
SCHEMBL24021451 0.82 IRAK1 (0.67) IRAK1MAP3K19IRAK4BCAT2ATR
SCHEMBL21328552 0.81 IRAK1 (0.76) IRAK1MAP3K19IRAK4BCAT2ATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3544970-A1 INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF Dana-Farber Cancer Institute, Inc. (US) 2019-10-02 EP disclosed
WO-2018098367-A1 INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-05-31 WO disclosed